WO2023144702 - COMBINATION THERAPY FOR CANCER
National phase entry:
Publication Number
WO/2023/144702
Publication Date
03.08.2023
International Application No.
PCT/IB2023/050600
International Filing Date
24.01.2023
Title **
[English]
COMBINATION THERAPY FOR CANCER
[French]
POLYTHÉRAPIE CONTRE LE CANCER
Applicants **
GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Inventors
FERRON-BRADY, Geraldine
KAISERMANN, Morrys C.
KREMER, Brandon
TOSOLINI, Alessandra
ZHOU, Xiaoou Linnette
Priority Data
63/302,924
25.01.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2907 | |
| EPO | Filing, Examination, Granting | 19222 | |
| Japan | Filing, Examination, Granting | 2775 | |
| South Korea | Filing, Examination, Granting | 3209 | |
| USA | Filing, Examination, Granting | 8140 |
Total:
36,253
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
This disclosure provides combination therapies comprising an anti-BCMA antigen binding protein, such as belantamab mafodotin; an immunomodulatory imide drug (IMiD); a proteasome inhibitor; and a corticosteroid. This disclosure also provides combination therapies for treating newly diagnosed multiple myeloma.[French]
La présente invention concerne des polythérapies comprenant une protéine de liaison à l'antigène anti-BCMA, telle que le belantamab mafodotin; un médicament imide immunomodulateur (IMiD); un inhibiteur du protéasome; et un corticostéroïde. La présente invention concerne également des polythérapies pour traiter un myélome multiple nouvellement diagnostiqué.